Table 1: Activities of melatonin and alpha lipoic acid on liver function markers of methotrexate-treated rats.


Treatment ALT (U/L) AST (U/L) ALP (U/L) LDH (U/L) GGT(U/L) TB (g/dL) CB (g/dL)

Control 25.6±2.00 bcd 22.4±2.22 bcd 27.6±3.33 bcde 23.5±3.00 bcd 0.21±0.01 bcde 4.66±0.11 bcd 2.00±0.22 bcde
MT 24.1±2.90 bcd 22.1±2.53 bcd 26.9±2.29 bcde 23.1±2.51 bcd 0.20±0.06 bcde 4.52±0.32 bcd 2.10±0.06 bcde
ALA 24.5±2.47 bcd 21.3±2.19 bcd 26.5±2.43 bcde 22.9±2.22 bcd 0.21±0.01 bcde 4.56±0.14 bcd 2.14±0.09 bcde
MT +ALA 25.0±2.01 bcd 21.0±2.97 bcd 25.9±2.56 bcde 22.4±2.01 bcd 0.20±0.09 bcde 4.44±0.32 bcd 2.17±0.07 bcde
MTX 88.9±6.44 acde 93.7±5.43 acde 99.5±6.11 acde 110.1±7.11 acde 0.90±0.05 acde 13.6±0.21 acde 8.72±1.00 acde
MT +MTX 58.0±2.21 abde 62.2±4.00 abde 69.1±4.31 abde 73.9±6.62 abde 0.60±0.07 abde 9.72±0.32 abde 6.70±0.52 abde
ALA +MTX 40.1±3.51 abce 42.0±3.62 abce 49.5±3.41 abce 46.4±3.13 abce 0.45±0.09 abce 6.23±0.50 abce 4.61±0.44 abce
MT + ALA+MTX 26.5±2.50 bcd 23.8±2.11 bcd 40.3±2.44 abcd 24.3±2.25 bcd 0.31±0.01 abcd 4.71±0.35 bcd 3.60±0.21 abcd

MTX: Methotrexate, MT: Melatonin, ALA: Alpha lipoic Acid, n=6, Data are expressed as Mean± SEM, a Difference at p<0.05 when compared to control, b Difference at p<0.05 when compared MTX, c Difference at p<0.05 when compared MT+MTX, d Difference at p<0.05 when compared ALA+MTX, e Difference at p<0.05 when compared MT+ALA+MTX